News und Analysen
![Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?: https://g.foolcdn.com/editorial/images/731652/gettyimages-88689535.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1lGYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e88162d2c42986a5f59b71daa868942cdae27efd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-88689535.jpg?locale=de)
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals; and Auvelity, an
![Why CRISPR Therapeutics Stock Is on Fire Today: https://g.foolcdn.com/editorial/images/731718/pig-taking-flight.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTBGYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--97b6afb580533447fee427c49296b5416982240b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pig-taking-flight.jpg?locale=de)
Why CRISPR Therapeutics Stock Is on Fire Today
Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio
![Why Catalent Stock Was a Disaster Today: https://g.foolcdn.com/editorial/images/731563/stethescope-atop-us-currency-and-coins.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHdFYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3a3e124d6753ff2181f4264c31b430431b4b394a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/stethescope-atop-us-currency-and-coins.jpg?locale=de)
Why Catalent Stock Was a Disaster Today
The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update
![Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Why Wall Street Took a Hit From These 2 NYSE Stocks: https://g.foolcdn.com/editorial/images/731485/chickens-gettyimages-576736468.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOThEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f1b1612e712ba9d27d89e1db889c422fa65015e1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chickens-gettyimages-576736468.jpg?locale=de)
Why Wall Street Took a Hit From These 2 NYSE Stocks
Monday was a relatively quiet day on Wall Street, with most major benchmarks seeing modest losses at midday. With key inflation and other economic data coming in the near future, investors are
![1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now: https://g.foolcdn.com/editorial/images/729512/businessmen-and-doctors-working-on-touchpad-in-a-hospital.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWtDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e8aa568033997f05181c8e409d5772ab8e019d2e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/businessmen-and-doctors-working-on-touchpad-in-a-hospital.jpg?locale=de)
1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now
If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of
![Looking for Steady, Passive Income? Buy AbbVie Stock: https://g.foolcdn.com/editorial/images/730634/a-doctor-and-patient-talk-to-each-other-during-an-appointment.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWNDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e980b53fedbe9596d1cac870e9b2b380fe1d491f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-and-patient-talk-to-each-other-during-an-appointment.jpg?locale=de)
Looking for Steady, Passive Income? Buy AbbVie Stock
Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth.
With 51 consecutive years of
![Better Gene Sequencing Stock: Illumina vs. Bionano Genomics: https://g.foolcdn.com/editorial/images/729509/two-scientists-work-at-lab-bench-with-scope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHNDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--747b56ccffd5c66862f7443652b931b511e20caa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-scientists-work-at-lab-bench-with-scope.jpg?locale=de)
Better Gene Sequencing Stock: Illumina vs. Bionano Genomics
Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the
![Why Illumina Fell 11.6% in April: https://g.foolcdn.com/editorial/images/731339/genetic-sequencing.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3dDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0a5b93a46da7eb04b3efa0a756617abc86918eec/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/genetic-sequencing.jpg?locale=de)
Why Illumina Fell 11.6% in April
Shares of Illumina (NASDAQ: ILMN) fell by 11.6% in April, according to data provided by S&P Global Market Intelligence.
The fall means that shares of the gene-sequencing company have only inched up
![3 Great Income Stocks That Retirees Should Love: https://g.foolcdn.com/editorial/images/731008/happy-older-couple-retirement-wealth-invest.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMjhDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a0b0cc415899e02c1274327ef9b3a23fe8df746e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/happy-older-couple-retirement-wealth-invest.jpg?locale=de)
3 Great Income Stocks That Retirees Should Love
Most Americans don't have to wait until they're retired to know that Social Security benefits won't be enough to maintain their current lifestyle. If they pay any attention to retirement planning
![Cigna Group (CI) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Cigna Group (CI) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Cigna Group (NYSE: CI)Q1 2023 Earnings CallMay 05, 2023, 8:30 a.m. ET
Operator
Source Fool.com
![2 Magnificent Dividend Stocks to Buy Before the Next Recession: https://g.foolcdn.com/editorial/images/730574/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODBCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7df0d179f13a8f2fde5cf25b689e574b8edea686/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=de)
2 Magnificent Dividend Stocks to Buy Before the Next Recession
Fears of a coming recession are probably about as high right now as they have been over the past year. That's because the U.S. Federal Reserve recently predicted an economic downturn would descend
![Should You Buy Novocure Stock Right Now?: https://g.foolcdn.com/editorial/images/730947/novocure-person-with-ttfields-on-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekVCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cb6680f4fb0e8951232a487dc6c9d6c728ac9e7c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure-person-with-ttfields-on-head.jpg?locale=de)
Should You Buy Novocure Stock Right Now?
Going, going, gone? That could be the question that Novocure (NASDAQ: NVCR) investors are asking these days. Shares of the oncology company plunged 56% in 2021. The stock slid 2% lower last year
![Why Karyopharm Therapeutics Shares Slumped Thursday: https://g.foolcdn.com/editorial/images/731087/using-a-stethoscope-listen-to-the-heartbeat-of-patient-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK29BYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e331e57b7e2d4d1087717c22acb69b3bf63586a9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/using-a-stethoscope-listen-to-the-heartbeat-of-patient-1.jpg?locale=de)
Why Karyopharm Therapeutics Shares Slumped Thursday
Shares of Karyopharm Therapeutics (NASDAQ: KPTI) were down more than 26% Thursday afternoon after the biotech company released first-quarter earnings and updated its guidance. The stock fell to its
![Vaccine Sales Are Falling. Should You Still Buy Pfizer?: https://g.foolcdn.com/editorial/images/730746/gettyimages-1252566534.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMm9BYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3f9eeac62ea7b0b6cba713dfda3f55ff962b99db/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1252566534.jpg?locale=de)
Vaccine Sales Are Falling. Should You Still Buy Pfizer?
Pfizer (NYSE:PFE) confirmed this week what everyone has been expecting. COVID-19 vaccine sales are falling drastically. The company reported a 77% drop in Comirnaty sales in the first quarter
![Why Regeneron Pharmaceuticals Stock Is Tanking Today: https://g.foolcdn.com/editorial/images/730998/crashing-arrow.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWNBYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a2a5fc3acbdca713644b805f37105180cbfb1f49/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/crashing-arrow.jpg?locale=de)
Why Regeneron Pharmaceuticals Stock Is Tanking Today
Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today. Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of
![Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q1 2023 Earnings CallMay 04, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Zoetis (ZTS) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Zoetis (ZTS) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q1 2023 Earnings CallMay 04, 2023, 8:30 a.m. ET
Operator
Source Fool.com
![2 High-Yielding Dividend Stocks Analysts Expect Will Rise by at Least 50%: https://g.foolcdn.com/editorial/images/730233/an-advisor-explaining-a-chart-to-clients.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1VBYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--00139217fbc23da7f2b56ea3d7d8ca08957247b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/an-advisor-explaining-a-chart-to-clients.jpg?locale=de)
2 High-Yielding Dividend Stocks Analysts Expect Will Rise by at Least 50%
Investors often gloss over dividend stocks, assuming that they offer nothing more than a recurring payout. But there are a couple of stocks that analysts are bullish about and that they believe
![2 Potentially Explosive Stocks to Buy in May: https://g.foolcdn.com/editorial/images/730672/dna-genetic-sequencing-biotech-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXorYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9002c99872a9c7cc39292dfc99f981917f2ff75a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-genetic-sequencing-biotech-1.jpg?locale=de)
2 Potentially Explosive Stocks to Buy in May
Stag Industrial (NYSE: STAG) and Vertex Pharmaceuticals (NASDAQ: VRTX) are off to a good start this year, and some industry tailwinds look to really boost shares in the coming years. Stag, which
![3 Top Healthcare Stocks to Buy in May: https://g.foolcdn.com/editorial/images/730742/scientists-high-five-smile.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTMrYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7cfef107b3e24fded03c3b6679012c71c0a33843/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-high-five-smile.jpg?locale=de)
3 Top Healthcare Stocks to Buy in May
Healthcare stocks always make a great addition to long-term portfolios. They offer you the potential to benefit from steady earnings growth over time. After all, regardless of the economic
![Why Amgen Stock Was Sickly Today: https://g.foolcdn.com/editorial/images/730881/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNWIrYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1e9fad231f51527fa6497eda24dbef7291025a7f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg?locale=de)
Why Amgen Stock Was Sickly Today
Investors are often encouraged when one of their companies bulks up by acquiring a peer. But that sentiment can turn sour if the takeover target stumbles.
This was the impetus behind Amgen's
![2 Things About AbbVie That Investors Are Ignoring: https://g.foolcdn.com/editorial/images/730557/gettyimages-1318178022.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0w5YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c8b07101eebfa4d8ba6b0e7598e6f9ccc091a996/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1318178022.jpg?locale=de)
2 Things About AbbVie That Investors Are Ignoring
Investors were ready for declines in AbbVie's (NYSE: ABBV) blockbuster immunology drug Humira. The product now is facing competition in the U.S. So, seeing a 26% drop in Humira's U.S. first-quarter
![Why Eli Lilly Stock Is Bolting Higher Today: https://g.foolcdn.com/editorial/images/730771/alzheimers.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1A5YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--95adba9a8202157f98bf0ae92013b00434e00cae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/alzheimers.jpg?locale=de)
Why Eli Lilly Stock Is Bolting Higher Today
Shares of the Illinois-based drugmaker Eli Lilly (NYSE: LLY) were up by 6% on heavy volume as of 1:45 p.m. ET Wednesday.
What sparked this latest rally? Ahead of the opening bell, Lilly announced
![Why ImmunoGen Stock Is Soaring Wednesday: https://g.foolcdn.com/editorial/images/730764/clovisnew.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0w5YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--77d4cca5a9bae0aef9ad077a8f1081b8a0b318ce/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/clovisnew.jpg?locale=de)
Why ImmunoGen Stock Is Soaring Wednesday
Shares of ImmunoGen (NASDAQ: IMGN) were up by 139% Wednesday morning after the company announced positive trial data concerning an ovarian cancer drug the company has in its pipeline. The biotech